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Background: Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may
be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and
second-line treatments for uncomplicated falciparum malaria in Côte d’Ivoire. Constant monitoring by National
Malaria Control Programme (NMCP) of drug efficacy is an important tool in establishing rational anti-malarial drug
policies in Côte d’Ivoire.
Methods: In an open label, randomized controlled clinical trial, children and adults were randomized to receive
AS-AQ or AL. Both drug regimens were given for three days, and follow-up was for 42 days. The primary endpoint
was the 42-day cure rate and was defined as proportion of patients with PCR-corrected cure rate after 42 days of
follow-up.
Results: A total of 383 patients who were attending the Anonkoua-koute (Abidjan), Petit Paris (Korhogo) and
Libreville (Man) hospitals and presenting with symptomatic acute uncomplicated falciparum malaria were randomized
to receive AS-AQ (188) and AL (195). The intention-to-treat analysis showed effectiveness rates of 94.7% and 96.4% for
AS-AQ and AL, respectively on day 42. After adjustment for PCR, these rates were 96.8% and 99%, respectively. At day
42, in per-protocol analysis, Adequate clinical and parasitological response (ACPR) PCR uncorrected was 97.8% and
97.4% for AS-AQ and AL, respectively. The PCR adjusted ACPR was 100% for each combination and both regimens were
well tolerated.
Conclusions: This study has shown the high efficacy of AS-AQ in patients of all ages with acute uncomplicated
falciparum malaria and AS-AQ was non-inferior to AL. Continuous efficacy monitoring is recommended.
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Artemisinin derivatives are advocated for use in anti-
malarial combination therapy because they quickly re-
duce the level of parasitaemia and hence the parasite
pool from which resistant Plasmodium falciparum
strains may arise [1]. Currently, artemether-lumefantrine
(AL) and artesunate-amodiaquine (AS-AQ) are the only
widely available drugs, which are recommended by most
malaria endemic countries in the treatment of uncom-
plicated falciparum malaria [1]. Prospective periodic
monitoring of the efficacy of anti-malarial treatments
by in vivo studies is part of post-marketing surveillance
[2]. Monitoring of artemisinin-based combination the-
rapy (ACT) becomes particularly important in the light
of emergence of artemisinin resistance in South-East
Asia [3,4].
In Côte d’Ivoire, AS-AQ and AL have been recom-
mended respectively in first- and second-line treatment
since 2005 following earlier studies [5-7]. Continued use
of amodiaquine or artesunate monotherapies, persistence
of substandard ACT in the private sector [8-10] and
resistance to artesunate and/or amodiaquine may
jeopardize the future use of AS-AQ and AL as an effec-
tive artemisinin-based combination therapy. Constant
diligent surveillance with the aim of monitoring the
susceptibility of malaria parasites to artemisinin, its deri-
vatives, and partner drugs in endemic areas is, therefore
essential. Recently, a molecular marker for the K13-
propeller gene has been identified for the monitoring of
artemisinin resistance and its derivatives [11]; but effective
monitoring still relies largely on in vivo studies with
adequate follow-up.
The main purpose of this study was to update the
baseline data from a randomized clinical trial assessing
the safety and efficacy of AS-AQ fixed-dose combination
tablets in comparison with a fixed-dose combination of
AL, the two drug combinations recommended by the
National Malaria Control Programme of Côte d’Ivoire.Methods
Study design
This study was a randomized, open-label, non inferiority
clinical trial comparing AS-AQ and AL and was carried
out according to current WHO protocol.Study sites
This trial was performed from September 2013 through
January 2014 at three health care centers in Anonkoua-
kouté (southern), Korhogo (northern) and Man (western)
in Côte d’Ivoire. Plasmodium falciparum transmission is
intense and perennial, with recrudescence during the rainy
season at every site. Plasmodium falciparum is the predo-
minant malaria-causing species.Patient screening, recruitment and exclusion
Patients presenting to the site were screened for eligibility
and invited to participate in the study if they met each
of the following criteria: aged at least six months; body
weight ≥5 kg; a history of fever in the previous 24 hours
or measured fever (axillary temperature ≥37.5°C or
rectal ≥38°C); mono-infection with P. falciparum, with
parasite density between 2,000–200,000 asexual parasites
per microlitre of blood; no other cause of fever than
suspected malaria; and no general danger signs or signs of
severe and complicated falciparum malaria as per WHO
guidelines [12]; able to take study drugs by the oral route;
able to attend clinic on stipulated days for follow-up;
and signed informed consent (by patient or responsible
caregiver).
Exclusion criteria consisted of: presence of severe and
complicated malaria as defined by WHO; a mixed plas-
modial infection, or concomitant disease masking assess-
ment of the response to anti-malarial treatment; full
course of AS-AQ or AL in the past 7 days; and known
hypersensitivity to any of the study drugs.
Baseline evaluation, randomization and treatment
At enrolment, the patient’s symptoms were evaluated.
Temperature (axillary or rectal) and weight were mea-
sured and a focused physical examination was performed.
A thick and thin blood smear for parasitaemia and a blood
sample on filter paper (Whatman 3MM) for later molecu-
lar analysis were collected before treatment. Patients were
randomly assigned to receive either AS-AQ or AL. Both
treatments were three-day oral regimens dosed by weight
according to the manufacturer’s instructions: AS-AQ 5
to <9 kg: one tablet/day of artesunate (AS) 25 mg/amodia-
quine (AQ) 67.5 mg; 9 to <18 kg: one tablet/day of AS
50 mg/AQ 135 mg; 18 to <36 kg: 1 tablet/day of AS
100 mg/AQ 270 mg; ≥36 kg: 2 tablets/day of AS 100 mg/
AQ 270 mg.
AL tablet strength was 20 mg artemether/120 mg
lumefantrine: 5 to <15 kg: 1 tablet/dose; 15 to <25 kg: 2
tablets/dose; 25 to <35 kg: 3 tablets/dose; ≥35 kg 4 tablets/
dose. AL was administrated twice a day.
The first dose was taken at enrolment, the second dose
eight hours later on day 0, and then two doses at 12-
hourly intervals for the subsequent two days. All tablets
were either swallowed whole or crushed with water. Yog-
hurt was then given with AL to the participants. The drug
administration was supervised by the research team.
Randomization was done by an independent statistician
using computer-allocated blocks of ten and was not strati-
fied. Individual treatment allocations were contained in-
side consecutively numbered sealed envelopes, which
were opened sequentially by a study investigator or clinical
research coordinator after the decision to enroll a subject
had been made by the study team. In the case where a
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administration, a repeat full dose was re-administered. If
vomiting persisted, the patient was withdrawn from the
study. A participant who was withdrawn due to vomiting
received rescue medication according to the Malaria Con-
trol Programme guidelines.
Sample size
Based on previous data for AL efficacy [13,14], efficacy
rate, defined as the PCR-adjusted parasitological cure
rate at day 42, was estimated of 95% for both treatments.
The maximal difference acceptable for the AS-AQ to be
considered as clinically non-inferior is 10% (absolute
value in percentage). For a statistical power of 90%
(β =10%), a risk α =5% and using 95% Confidence Inter-
val, sample size for each arm was 162 per treatment
group. Allowing for 10% incidence of premature with-
drawals, the total number of patients required would be
178 per treatment group.
Laboratory evaluations
Thick and thin blood smears were stained with 10%
Giemsa for 30 minutes. Parasite density was determined
by reading the thick blood smear and counting the num-
ber of asexual parasites and the number of leukocytes
for 200 high-powered fields. Slides were considered
negative if no parasite was detected after reading 200
high-powered fields. Presence of gametocytes was also
recorded. Thin blood smears were reviewed for non-
falciparum infections. Two microscopists independently
read all slides and parasite densities were calculated by
averaging the two counts.
Readings with discordant results (difference in species
diagnosis, difference in parasite density of 25%, or any
difference that affected recruitment or study outcome)
were re-examined by a third microscopist; the parasite
density was calculated by averaging the two closest dens-
ities while the final parasite species was determined by
the two concordant reads.
Blood samples were drawn for haematology (haemoglo-
bin level, leucocyte count, haematocrit) and biochemistry
(serum alanine aminotransferase, aspartate aminotrans-
ferase, total bilirubin, glycaemia, urea and creatinine)
assessments on day 0, 3 and on the day of recurrent
parasitaemia. Genotyping was done according to inter-
national recommendations [15].
Blood spots on Whatman 3 M filter paper were pre-
pared for PCR genotyping. Multiplicity of infection was
assessed using three polymorphic loci (merozoite surface
proteins 1 and 2 and glutamate-rich protein). Briefly, filter
paper blood samples collected on the day of enrolment
and on the day of failure were analysed for polymorphism
of merozoite surface protein-1 (msp-1) and merozoite
surface protein-2 (msp-2) using nested-PCR as previouslydescribed [15]. Possible outcomes were new infection or
recrudescence. A “new infection” is a subsequent occur-
ring parasitaemia in which all the alleles in parasites from
the post-treatment sample are different from those in the
admission sample, for one or more loci tested. In a
“recrudescence,” at least one allele at each locus should
be in common for both paired samples.
When no amplification was observed for either of
the paired samples, the outcome was classified as
indeterminate.
Follow-up procedures and classification of treatment
outcomes
The patients returned on days 1 and 2 to complete the
drug administration and for clinical assessment. They
were also given appointment for days 3, 7, 14, 21, 28, 35
and 42 for clinical examination, blood smears and filter
paper confection. Patients who failed to report at the
clinic for the scheduled visit were followed to their
residence by trial field workers. They were also asked to
return to the clinic on any other day if new complaints,
or any change in their condition.
Treatment outcomes were classified according to the
WHO guidelines for areas of intense transmission as ad-
equate clinical and parasitological response (ACPR),
early treatment failure (ETF), late clinical failure (LCF)
and late parasitological failure (LPF) [2]. Failure was
defined as the sum of ETF, LCF and LPF. The primary
endpoint was the 42-day cure rate and was defined as
proportion of patients with PCR-corrected cure rate
after 42 days of follow-up. Secondary efficacy endpoints
included, fever and parasite clearance time, gametocytae-
mia (prevalence and density) at day 7, 14, 21 and 28.
Safety assessments
Safety outcomes included risk of adverse events. At each
follow- up visit, any new or worsening event and laboratory
results were assessed passively and actively. An adverse
event was defined as any unfavorable and unintended sign
(including an abnormal laboratory finding), symptom, or
disease temporarily associated with the use of an investiga-
tional product, not present on day 0, but occurred during
follow-up, or was present on day 0 but became worse dur-
ing follow-up. Serious adverse event was defined as any
event that resulted in patient hospitalization, death, life
threatening experience, persistent/significant disability, or
specific medical/surgical intervention to prevent serious
outcome.
Statistical analysis
Data generated were recorded in a log book and individual
participants case record files. Data were entered and ana-
lysed with EPI-Info version 6.4. An intention to treat
(ITT) and per protocol (PP) analysis were done. The ITT
Artesunate-amodiaquine 
n = 188 
Artemether-lumefantrine 
n= 195 
Complete treatment and available 
for follow-up day 42 (n = 182) 
Complete treatment and available 
for follow-up day 42 (n = 193) 
2 Lost to follow up 3 Lost to follow up 1 
Protocol deviation 2 
withdrawn consent 
780 no malaria  18 No falciparum 
97 no Informed Consent 
97 Low parasitaemia  
86 high parasitaemia 
87 travel , 58 Hb<8g/Dl 
1,626 assessed for 
eligibility 
383 patients randomized 
Figure 1 Trial profile.
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any study medication and was the same as the safety
population. Patients with major violations and patients lost
during the follow-up or withdrawn (due to an adverse event
or to the use of another drug with anti-malarial activity or
withdrawal consent) have been considered as failure. The
PP population included patients that received a full course
of study medication, had a known day-42 primary endpoint,
and did not violate the protocol so as to impair evaluation
of the primary endpoint. Those lost to follow up, and the
withdrawals of consent were excluded from the per
protocol analysis. Frequencies were compared by either
chi-squared or Fisher’s exact tests, as appropriate, and
continuous variables by Student’s t-tests when the data
are normally distributed. No normally distributed data
were transformed to normality.Table 1 Baseline characteristics in the ITT cohort
AS-AQ AL p value
Number of patients 188 195 -
Mean age (SD) 15.7 (±16.2) 14.4 (±12.1) 0.36a
Sex ratio (M/F), 1.04 1.35 0.09b
Mean weight,
kg (SD)
36.1 (±23.3) 36.6 (±21.8) 0.80b
Mean temperature,
°C (SD)
38.3 (±0.81) 38.3 (±0.9) 0.74b
GM parasite count,
μL (SD)
38,752.8 (±47,806.9) 41,371 (±65,165.8) 0.65b
Notes: achi-squared test; bStudent’s t-test.
Abbreviations: AS-AQ, artesunate-amodiaquine; AL, artemether-lumefantrine;
GM, geometric mean, ITT, intention to treat.Ethical issues
The study was conducted in accordance with the local
laws and regulations, International Conference on
Harmonization - Good Clinical Practice (ICH-GCP). The
protocol was reviewed and approved by the Comité
National d’Ethique et de Recherche de Côte d’Ivoire
(N°56/MSLS/CNER-dkn). Written informed consent was
obtained from participants/parents/guardians. In case of
an illiterate patient, his/her thumb impression and signa-
ture of an independent witness were obtained.
Results
Study trial profile and baseline characteristics
The trial profile is summarized in Figure 1. A total of
1,626 patients were screened of whom 383 fulfilled the
inclusion criteria: 188 in the AS-AQ group and 195 in the
AL group. Three Lost to follow up, one Protocol deviation
and two cases of withdrawn consent were registered in the
AS-AQ group when only two lost to follow up were noted
in AL group. A total of 182 patients ended up in AS-AQ
group and 193 patients in AL group.
The baseline characteristics in the ITT cohort of both
groups were similar (Table 1) regarding age, gender,
weight, axillary or rectal temperature and parasite density.
The average age was 15.7 ± 16.2 in AS-AQ group and
14.4 ± 12.1 in AL group (p = 0.36). Average weight was
36.1 ± 23.3 in AS-AQ group and 36.6 ± 21.8 in AL group
(p = 0.80). The sex ratio was not significantly different: 1
in AS-AQ group and 0.7 in AL group (p = 0.09). Overall,
both groups of patients were comparable at the inclusion
































Follow up visit day
ASAQ
AL
Figure 2 Proportion of patients with fever during follow up. Note: No significant differences were found for the proportions of subjects with
fever between the two treatment regimens from baseline to day 28 (P >0.05 Fisher’s exact test or chi-squared test as appropriate). Abbreviations:
AL, artemether-lumefantrine; AS-AQ, artesunate-amodiaquine.
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As shown in Figure 2, the proportion of participants
without fever was similar on days 2 and 3. On day 2, the
fever clearance rates were 98.9% (180 of 182) and 99%
(191 of 193) in the AS-AQ and AL groups, respectively































Figure 3 Proportion of patients with parasites during follow up. Note
between the two treatment arms: 98.9% and 99.5% (P =0.49) for those rece
100% in the two arms. Abbreviations: AL, artemether-lumefantrine; AS-AQ,182) and 99.5% (192 of 193). Both treatments resulted
in rapid clearance of parasites (Figure 3) as parasite
clearance rates on day 2 were 98.9% (180 of 182) and
99.5% (192 of 193) in the AS-AQ and AL groups, re-
spectively. At day 3 parasite clearance rate was 100% in




: The proportion of participants who were aparasitaemic was similar




























Follow up visit day
ASAQ
AL
Figure 4 Proportion of patients with gametocytes during follow-up. Abbreviations: AL, artemether-lumefantrine;
AS-AQ, artesunate-amodiaquine.
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At enrolment, gametocytes were detected in the
peripheral blood of 10 (5.3%) and 9 (4.6%) patients in
the AS-AQ and the AL group respectively. The gam-
etocyte carriage rate was 3.3% (six patients) and 2.1%
(four patients) on day 3. All patients were free of
gametocytes from day 28 to day 42 in the AS-AQ
group and from day 14 to day 42 in the AL group
(Figure 4).
Five patients did not have gametocytes at enrolment
developed gametocytaemia after treatment: two pa-
tients in AS-AQ group and one AL group at day 1, at
day 2 Two patients in AS-AQ group and one patient at




Patients seen at day 42 182/188 (96.8%)
Missing 06/188 (3.2%)
Crude failure rate at day 42 04/188 (2.1%)
Crude cure rate at day 42 178/188 (94.7%)
PCR adjusted failure rate at day 42 06/188 (3.2%)
PCR adjusted cure rate at day 42 182/188 (96.8%)
PP analysis
Patients seen at day 42 182
Crude failure rate at day 42 04/182 (02.2%)
Crude cure rate at day 42 178/182 (97.8%)
PCR adjusted failure rate at day 42 0/182 (0%)
PCR adjusted cure rate at day 42 182/182 (100%)Therapeutic efficacy
No early treatment failure (ETF) was observed in either
study group. Adequate clinical and parasitological re-
sponses were similarly high in both treatment groups.
Until day 42, adequate clinical and parasitological re-
sponse was observed in patients: 97.8% (178/182) in the
ASAQ group and 97.4% (188/193) in the AL group.
Nine of three hundred seventy five patients who com-
pleted at least 42 days follow-up had reappearance of
parasitaemia (five in the AL group, four AS-AQ group)
after initial clearance of parasitaemia between days 21
and 42. Among the nine patients with recurrent parasit-
aemia after day 21, PCR genotyping was successfully













Table 3 Treatment outcome stratified by site
Treatment outcome stratified by locality Artesunate/Amodiaquine Artemether/Lumefantrine p value
ABIDJAN (130 patients) 65 65
ITT analysis
Crude failure rate at day 42 3/65 (4.61%) 00/65 (00%) 0.07
Crude cure rate at day 42 62/65 (95.4%) 65/65 (00%) 0.07
PCR adjusted failure rate at day 42 1/65 (1.5%) 00/65 (00%) 0.31
PCR adjusted ACPR at day 42 64/65 (98.5%) 65/65 (100%) 0,31
% difference 1,5 [−1 ; 4]
PP analysis
Crude failure rate at day 42 2/64 (3.1%) 00/65 (00%) 0.31
Crude cure rate at day 42 62/64 (96.9%) 65/65 (00%) 0,31
PCR adjusted failure rate at day 42 00/64 (00%) 00/65 (00%) 1
PCR adjusted ACPR at day 42 64/64 (100%) 65/65 (100%) 1
% difference 0
KORHOGO (128 patients) 64 64
ITT analysis
Crude failure rate at day 42 03/64 (4.7%) 03/64 (4.7%) 1
Crude cure rate at day 42 61/64 (95.3%) 61/64 (95.3%) 1
PCR adjusted failure rate at day 42 00/64 (00%) 00/64 (00%) 1
PCR adjusted ACPR at day 42 61/64 (95.3%) 64/64 (100%) 0.07
% difference 4,7[0 ; 9]
PP analysis
Crude failure rate at day 42 00/61 (00%) 03/64 (4.7%) 0.07
Crude cure rate at day 42 61/61 (100%) 61/64 (95.3%) 0.07
PCR adjusted failure rate at day 42 00/61 (00%) 00/64 (00%) 1
PCR adjusted ACPR at day 42 61/61 (100%) 64/64 (100%) 1
% difference 0
MAN (125 patients) 59 66
ITT analysis
Crude failure rate at day 42 02/59 (3.4%) 4/66 (6%) 0.47
Crude cure rate at day 42 55/59 (93.2%) 62/66 (94%) 0.47
PCR adjusted failure rate at day 42 02/59 (3.4%) 02/66 (3%) 0.90
PCR adjusted ACPR at day 42 57/59 (96.6%) 64/66 (97%) 0,90
% difference 0,4[−5 ; 6]
PP analysis
Crude failure rate at day 42 02/57 (3.5%) 02/64 (3.1%) 0.90
Crude cure rate at day 42 55/57 (96.5%) 62/64 (96.9%) 0.90
PCR adjusted failure rate at day 42 00/57 (00%) 00/64 (00%) 1
PCR adjusted ACPR at day 42 57/57 (100%) 64/64 (100%) 1
% difference 0
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lysis was 96.8% and 99% for AS-AQ and AL, respect-
ively. In PP analysis, this rate was 100% for both drugs.
Thus, the non-inferiority of AS-AQ was shown both in
ITT and PP analysis (Table 2). Regarding treatmentfailure, after PCR correction, 2.2% (4 patients) and 2.6%
(5 patients) in AS-AQ group and in AL group, respect-
ively, were considered as reinfections. Any difference was
obtained in the therapeutic efficacy analysis done per site
(Table 3).
Table 4 Clinical adverse events in the ITT population
Adverse
events
AS-AQ AL Fisher’s Exact Test
n % 95% IC n % 95% IC p value
Asthenia 95 50.5 41.72-59.33 43 22.1 14.75-29.34 <0.0001
Headache 18 9.6 04.39-17.70 22 11.3 05.71-16.84 0.58
Anorexia 40 21.3 14.06-28.47 20 10.3 04.91-15.58 0.003
Abdominal pain 26 13.8 07.74-19.89 13 6.7 02.27-11.04 0.02
Nausea 6 3.2 0.09-06.28 0 0 - 0.01
Vomiting 16 8.5 03.59-13.42 2 1 - 0.001
Drowsiness 5 2.7 - 1 0.5 - 0.09
Dizziness 14 7.4 02.82-12.05 2 1 - 0.002
Rash 0 0 - 1 0.5 - 0.32
Notes: The most commonly reported and possibly drug-related adverse events to both combination therapies were gastrointestinal effects (abdominal pain,
anorexia, nausea, abdominal pain, and vomiting); P values were obtained by Fisher’s exact test.
Abbreviations: AL, artemether-lumefantrine; AS-AQ, artesunate-amodiaquine.
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Overall, AS-AQ and AL were well tolerated in this
study. Most of the recorded adverse events were signs
and symptoms of malaria, thereby making their assess-
ment difficult. None of the patients presented with
serious adverse events that necessitated withdrawal from
the study or hospitalization was observed in both
groups. Adverse effects associated with the gastrointes-
tinal tract, such as anorexia (21.3% vs 10.3%), Nausea
(3.2% vs 0%) vomiting (8.5% vs 1%), diarrhoea (5.8 %,)
and abdominal pain (13.8% vs 6.7%) were more frequent
in the AS-AQ group compared to the AL group (p <
0.05). Others clinical adverse events were asthenia
(50.5% vs 22.3%) and dizziness (7.4% vs 1%) and were
more frequent in AS-AQ group (p < 0.05). All of these
events were described as mild or moderate. Table 4
shows details of the distribution of clinical AEs recorded
during the study.
Frequent laboratory AEs included mild or moderate
hyperbilirubenia, hypercreatinemia or anaemia in both
arms at day 3 was observed (Table 4). The prevalence of
anaemia at baseline and day 3 was, respectively, 58.6%
and 78.9.3% in the AS-AQ group. In the AL group this
prevalence was 57.4% and 79.5% at day 0 and day 3,Table 5 Biological parameters evolution between day 0 and d
AS + AQ
Parameters D0 D3
Mean Hb level (g/dL) (±SD) 10.53 (±1.98) 9.39 (±2
Anaemia (Hb level <11 g/dL) (%) 58.6 70.9
Patient with abnormal ALAT (<40UI/L) (%) 79.79 90.40
Patient with abnormal ASAT (<40UI/L) (%) 55.32 84.07
Mean bilirubin level (±SD) 06.45 (±6.65) 08.26 (±
Mean creatinine level (±SD) 9.50 (±5.75) 16.03 (±1
Abbreviations: AS-AQ, artesunate-amodiaquine; AL, artemether-lumefantrine; D, day
amino transferase.respectively. Liver abnormalities were almost exclusively
asymptomatic and mildly increased AST and/or ALT
values. More participants presented increase of AST
and/or ALT at day 3 compared to day 0 in both arms
(Table 5).
Discussion
Introduction of highly efficacious artemisinin-based
combination therapy (ACT) as first-line treatment in
most malaria endemic countries has contributed to
recent notable reversals of trends in childhood morbidity
and mortality [1,16]. Because of the prominent value of
ACT in current malaria control programmes, the emer-
gence of parasite resistance to artemisinins and the asso-
ciated compromised efficacy of ACT would pose a major
public health problem. The recently reported emergence
of artemisinin-resistant malaria characterized by slow
initial parasite clearance and high rates of recrudescent
infections in Western Cambodia and other countries in
South East Asia is, therefore, of great concern [3,17,18].
The present study was conducted to provide support-
ing evidence for the clinical efficacy of AS-AQ and AL,
which were adopted and implemented as anti-malarial
drug policy in Côte d’Ivoire since 2005. These two formsay 3
AL
P value D0 D3 p value
.74) <10−4 10.57 (±1.84) 8.72 (±2.88) <10−4
0.014 57.4 79.5 <10−4
0.012 75.90 81.89 0.20
<10−4 51.79 79.47 <10−4
8.30) 0.14 5.50 (±4.81) 8.89 (±9.93) 0.01
7.64) <10−4 8.70 (±2.51) 13.68 (±10.86) <10−4
; Hb, hemoglobin; ASAT, aspartate amino transferase; ALA, alanine
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vices and widely available and taken for self-medication
since this date. Current international guidelines advo-
cated the need to monitor ACT regularly in order to
detect early signs of declining efficacy, which can have
implications for policy markers [2].
The study was based on the in vivo efficacy using 42-
follow up days protocol of two different forms of ACT,
AS-AQ and AL among children and adults with uncom-
plicated falciparum malaria in NMCP three sentinels sites
(Abidjan in the south, Korhogo in the north and Man in
the west) in Côte d’Ivoire. The day 42 genotyping-adjusted
cure rate estimates of AS-AQ and AL reached 100% for
each drug. Both treatments were well above the WHO
recommended 90% threshold for treatments in uses [2].
These results are in agreement with earlier studies in
Côte d’Ivoire that have shown for both combinations
high cure rate [6,19-21] and are also consistent with the
high cure rates that have been reported for ACT in other
malaria-endemic areas of Africa [19,22-25]. In addition to
high cure rates, most of the other parameters for assessing
efficacy such as PCT and FCT were also comparable
between the two groups.
The proportion of parasitaemic patients on day 3 has
been reported as an interesting indicator for monitoring
artemisinin resistance [26]. Although this indicator re-
quires large sample sizes and accurate timing of sample
collection for precise estimates, PCT for both AS-AQ
and AL in the present study, was nevertheless reassur-
ing. It is, however, noteworthy that the FCT and PCT in
the present study were inaccurate measures because
body temperature and parasite density were measured
every 24 h from day 0 to day 3 and not every 6 or 8 h as
in some other published studies [27]. The use of more
accurate estimations of parasite clearance rates with re-
cently developed tools should be preferred but demand
repeated parasitaemia measures [28].
Mild asthenia AEs were very frequently reported in
both treatment arms, with almost twice as many patients
in the AS + AQ arm than in the AL arm (50.5% vs
22.3%), p <0.05). Asthenia is considered among common
undesirable effects of AS-AQ [29]. No differences in
fatigue or asthenia between AS-AQ and AL in some stud-
ies [5,25] were observed. AS-AQ presents the advantage
of requiring one intake per day without fatty food while
AL is twice per day with fatty food. However, the tolerabi-
lity, in particular asthenia and gastro-intestinal disorders
may impact the effectiveness of the treatment and should
be assessed, particularly while used in home management
of malaria [30] or as intermittent preventive therapy in
children [31].
Regarding biological aspects, a significant increase in
the number of patients presenting an Anaemia, abnor-
mal ASAT and ALAT has been observed in both groups.These abnormalities have been also observed in other
studies with AS-AQ and AL [20,23].
Safety and tolerability monitoring of AS-AQ, AL and
other forms of ACT should continue in a standardized
manner. Pharmacovigilance networks are not imple-
mented in most settings where ACT is routinely used.
There are some limitations concerning this study. Drug
levels were not tested and only first doses of AL were
observed. As absorption is fat dependent, fatty food was
provided and patients were precisely instructed how and
when to take the rest of the medication. However, intake
was not directly controlled.
Conclusion
AS-AQ and AL were safe and effective drugs for the treat-
ment of uncomplicated falciparum malaria in the study
areas nine years after the deployment of these drugs. AS-
AQ and AL showed rapid fever and parasite clearance and
the efficacy met the WHO criteria for efficacy (>90%) in
malaria endemic regions. The efficacy of these two differ-
ent forms of ACT needs to be carefully monitored period-
ically since the treatment failures can occur due to
resistance as well as sub-therapeutic levels due to inad-
equate absorption or low adherence to the drug.
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